Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rupatadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 18/20 | 1.00 |
| ▸ | PTAFR known ✓ | P25105 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | FNTA | P49354 | 2/20 | 0.60 |
| ▸ | FNTB | P49356 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rupatadine SCHEMBL30730975 | 1.00 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL29400290 | 1.00 | HRH1 (1.00) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL1649670 | 0.99 | HRH1 (0.98) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL28585002 | 0.99 | HRH1 (0.98) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL28086201 | 0.95 | HRH1 (0.90) | HRH1PTAFRKCNH2FNTAFNTB | |
| SCHEMBL16385871 | 0.93 | HRH1 (0.87) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL31116805 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL29602857 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL19474963 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB | |
| Rupatadine SCHEMBL180512 | 0.93 | HRH1 (0.86) | HRH1PTAFRKCNH2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2582 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4633613-A1 | PHARMACEUTICAL COMPOSITION COMPRISING RUPATADINE AND MONTELUKAST | NOUCOR HEALTH S.A. (ES) | 2025-10-22 | — | — | EP | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| US-20250275951-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2025-09-04 | — | — | US | claimed |
| EP-4580659-A1 | METHODS FOR TREATING CHRONIC INDUCIBLE COLD URTICARIA BY ADMINISTERING AN IL-4R ANTAGONIST | Sanofi Biotechnology (FR) | 2025-07-09 | — | — | EP | claimed |
| US-20250177398-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-05 | — | — | US | claimed |
| CN-120091829-A | Methods of treating chronic induced cold urticaria by administering IL-4R antagonists | 赛诺菲生物技术公司 | 2025-06-03 | — | — | CN | claimed |
| US-20030078517-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| US-5476856-A | Treatment of PAF and histamine-mediated diseases with 8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine | J. URIACH & CIA. S.A. (ES) | 1995-12-19 | — | — | US | claimed |
| EP-0577957-B1 | 8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine | URIACH & CIA SA J (ES) | 1995-07-12 | — | — | EP | claimed |
| US-5407941-A | Platelet activating factor antagonist and antihistamine; useful for treating asthma and allergic disorders | J. URIACH & CIA. S.A. (ES) | 1995-04-18 | — | — | US | claimed |
| EP-0577957-A1 | 8-Chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine | J. URIACH & CIA. S.A. (ES) | 1994-01-12 | — | — | EP | claimed |